Back on July 25th of last year I wrote an article recommending people 'ease off' medical conglomerate Johnson & Johnson. My reasoning was based mostly off valuation. The stock was at multi-year highs and was at a big premium to its average ten-year valuation.
Courtesy of Google Finance. (NYSE:JNJ)
That ended up being a pretty good call. As you can see, since that time shares of J&J have dropped to almost $110, before recovering to a 'candlestick' top that hit almost $130.
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that Matthew S. Rheingold has been elevated from
Einhorn, Barbarito, Frost & Botwinick, PC, is pleased to announce that partners Thomas J. Snyder and Matheu D. Nunn
Mark H. Anania, a partner at McCarter & English, LLP, has been named President of the New Jersey Intellectual Property Law Association
Cohen Seglias Pallas Greenhall & Furman PC is pleased to announce that Anthony H. Chwastyk has joined the
For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile
Connect© Copyright 2026 citybuzz
